pentobarbital will decrease the level or result of nisoldipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will lower the level or result of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
pentobarbital will lessen the extent or result of clarithromycin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Not known.
pentobarbital will reduce the level or influence of finasteride by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Not known.
pentobarbital will lower the extent or effect of bazedoxifene/conjugated estrogens by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
Contraindicated (one)pentobarbital will minimize the extent or outcome of roflumilast by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the level or outcome of pimozide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.
pentobarbital will decrease the extent or effect of cilostazol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will minimize the extent or effect of budesonide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use more info Caution/Keep an eye on.
This drug may interfere with the absorption of orally administered griseofulvin, reducing its blood concentrations; effects of blood level reduction unfamiliar; preferable to prevent concomitant administration of such drugs
pentobarbital will lessen the level or impact of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Mysterious.
Hypnotic doses of such barbiturates usually do not show up to considerably impair uterine activity through labor; full anesthetic doses of barbiturates reduce the drive and frequency of uterine contractions; administration of sedative-hypnotic barbiturates towards the mom during labor might lead to respiratory despair in the new child
Possible for false favourable exam effects if macimorelin and strong CYP3A4 inducers are coadministered. Discontinue strong CYP3A4 inducer, allowing for for adequate washout time, prior to testing.
Reserve concomitant prescribing of those drugs in people for whom other therapy possibilities are insufficient. Limit dosages and durations into the minimal required. Keep an eye on carefully for indications of respiratory despair and sedation.